Skip to main content


  • Meeting abstract
  • Open Access

Continuous long-term growth of plasmacytoid dendritic cells following in vitro infection with HTLV-1

  • 1Email author,
  • 2,
  • 3,
  • 1,
  • 1,
  • 4,
  • 3 and
  • 2
Retrovirology20118 (Suppl 1) :A174

  • Published:


  • Interferon
  • Viral Protein
  • Infected Individual
  • FACS Analysis
  • Integration Site

Plasmacytoid dendritic cells (pDCs) isolated from HTLV-1-infected individuals express viral proteins and can infect CD4+ T cells in vitro [1], and the proviral load in pDCs parallels the PBMC proviral load in infected individuals [2], suggesting a role for these cells in HTLV-1 transmission and persistence. We recently generated immortalized cell lines from primary pDCs infected with HTLV-1.

Peripheral blood pDCs can survive in ex vivo culture for a limited time in the presence of IL-3. Following infection with cell-free virus, pDC were cultured with activated CD4+ T cells, and separated by immunomagnetic beads. Cells capable of continuously proliferating in the absence of IL-3 were isolated and characterized. FACS analysis revealed that these cells are phenotypically similar to pDCs (CD123+, BDCA2+, CMKLR1+, CD3-, CD19-, CD14-). Preliminary studies suggest that these cells spontaneously produce cytokines and chemokines expressed by pDCs. These pDC-like cells produce high levels of HTLV-1, as determined by ELISA analyses of culture supernatants and transmission EM and, like freshly isolated pDCs, can efficiently transmit HTLV-1 to T cells. As previously shown for HTLV-1-infected T cells [3], expression of HTLV-1 in these pDC-like cells is markedly decreased following exposure to type 1 interferons. Studies to characterize the viral integration sites and to examine expression levels of proteins previously shown to be altered in HTLV-1-transformed T cells are currently in progress. The in vitro generation of immortalized HTLV-1-infected pDC-like cells capable to transmitting the virus to T cells support the notion that pDCs could be an in vivo reservoir for HTLV-1.

Authors’ Affiliations

Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, Frederick, Maryland 21702, USA
Cancer and Inflammation Program, National Cancer Institute-Frederick, Frederick, Maryland 21702, USA
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland 20892, USA


  1. Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW: Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med. 2008, 14: 429-436. 10.1038/nm1745.View ArticlePubMedGoogle Scholar
  2. Azakami K, Sato T, Araya N, Utsunomiya A, Kubota R, Suzuki K, Hasegawa D, Izumi T, Fujita H, Aratani S, Fujii R, Yagishita N, Kamijuku H, Kanekura T, Seino K, Nishioka K, Nakajima T, Yamano Y: Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood. 2009, 114: 3208-15. 10.1182/blood-2009-02-203042.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Kinpara S, Hasegawa A, Utsunomiya A, Nishitsuji H, Furukawa H, Masuda T, Kannagi M: Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J Virol. 2009, 83: 5101-8. 10.1128/JVI.02564-08.PubMed CentralView ArticlePubMedGoogle Scholar


© Jones et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.